Fagerberg, J <br/><br/>
Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Mar 1994 
 - 149-59 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-7004 
<br/><br/><label>Standard No.: </label>10.1007/BF01525635  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Anti-Idiotypic--immunology<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Neoplasm--therapeutic use<br/>Antigens, Neoplasm--immunology<br/>Antigens, Tumor-Associated, Carbohydrate--therapeutic use<br/>Colorectal Neoplasms--immunology<br/>Female<br/>Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Hypersensitivity, Delayed--immunology<br/>Immunity, Cellular<br/>Immunoglobulin Idiotypes--immunology<br/>Lymphocyte Activation<br/>Male<br/>Middle Aged<br/>Recombinant Fusion Proteins<br/>T-Lymphocytes--immunology